FOLH1 and posterior cortical atrophy: Positron emission tomography (PET) targeting the prostate-specific membrane antigen (PSMA PET) with the two FDA approved radiopharmaceuticals (68Ga-PSMA-11 and 18F-FCPyL) [2, 3] has become the first-line imaging technique to stage and restage PCa and is recommended by current clinical guidelines (National comprehensive cancer network—NCCN Guidelines—Version 1.2023).